SCHEMBL346759

SCHEMBL346759

CC(C)(C)NC(=O)c1ccc(CN2CCNCC2)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
GAA P10253 1/20 0.53
ALDH1A1 P00352 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HTT P42858 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
LMNA P02545 1/20 0.46
KMT2A Q03164 2/20 0.44
USP2 O75604 2/20 0.42
TSHR P16473 1/20 0.42
CXCR4 P61073 5/20 0.41
HRH3 Q9Y5N1 3/20 0.41
MEN1 O00255 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
ADRA2C P18825 1/20 0.41
CCR2 P41597 1/20 0.41
CXCL12 P48061 1/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347202 0.84 ALDH1A1 (0.54) KDM4EGAAALDH1A1NPSR1HTT
SCHEMBL348744 0.80 ALDH1A1 (0.53) KDM4EGAAALDH1A1NPSR1HTT
SCHEMBL1827441 0.79 KDM4E (0.50) KDM4EGAAALDH1A1NPSR1HTT
Tert-Butyl Formate SCHEMBL27834703 0.76 ALDH1A1 (0.65) KDM4EGAAALDH1A1NPSR1HTT
SCHEMBL1017905 0.73 CHRM3 (0.61)
SCHEMBL21043976 0.73 HTT (0.60) KDM4EGAAALDH1A1NPSR1HTT
SCHEMBL348145 0.73 KDM4E (0.43) KDM4EGAAALDH1A1NPSR1HTT
Hydrochloric Acid SCHEMBL1018725 0.72 CHRM3 (0.60)
SCHEMBL23011745 0.71 ALDH1A1 (0.54) KDM4EGAAALDH1A1NPSR1HTT
SCHEMBL6584091 0.71 KDM4E (0.97) KDM4EGAAALDH1A1NPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 US disclosed
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 US disclosed
EP-2318368-B1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES MERCK SHARP & DOHME (NL) 2013-10-16 EP disclosed
EP-2318368-B1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES MERCK SHARP & DOHME (NL) 2013-10-16 EP disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 US disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES NPC1, ABCB11, NPC1L1 KDM4E 3947/4885GAA 3420/4885ALDH1A1 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.